Rani Therapeutics Holdings, a clinical-stage biotherapeutics company, announced a registered direct offering of Class A common stock priced at-the-market under Nasdaq rules. The offering includes 12.48 million shares and pre-funded warrants for 6.21 million shares, priced around $1.07 each, led by a sovereign wealth fund and healthcare-focused investors. The gross proceeds are expected to be approximately $20 million, which will support Rani's development of its oral biologics delivery technology, including the RaniPill®. The offering is expected to close around May 27, 2026, subject to customary conditions.
Baker Hughes has extended and expanded its contract with Petrobras to provide integrated well construction solutions in Brazil's Santos Basin. The company will deploy advanced technologies like the AutoTrak rotary steerable system and Dynamus drill b...
California Resources Corporation has completed the first CO₂ injection at Carbon TerraVault I, California's first operational carbon capture and storage (CCS) project located in Kern County. This milestone marks a significant step toward California's...
REalloys Inc. has committed $20.6 million to upgrade the Saskatchewan Research Council's rare earth processing facility, increasing production capacity for critical rare earth metals like Neodymium-Praseodymium, Dysprosium, and Terbium. These upgrade...
Cartesian Therapeutics secured up to $150 million in non-dilutive financing from K2 HealthVentures, with an initial $50 million tranche extending its cash runway into 2028. This funding supports the advancement of multiple clinical trials for its CAR...
Rocket Lab's stock surged following strong Q1 2026 results, with revenue up 63.5% year-over-year to $200.3 million and a record backlog of $2.2 billion. The company also secured a $90 million contract from the U.S. Space Force to design and manufactu...
